Acute pancreatitis following endoscopic retrograde cholangiopancreatography. Acute pancreatitis, unspecified
Conditions
Interventions
Intervention 1: Intervention group (Indomethacin + octreotide group): Octreotide will be infused 100 micrograms intravenously during ERCP as a state and then 50 micrograms intravenously every six hour
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Participants aged between 18 and 75 years Participants with normal levels of amylase and lipase before undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP). Presence of high-risk criteria for post-ERCP pancreatitis based on UpToDate recommendations Multiple cannulations during ERCP History of previous pancreatitis following ERCP Dysfunction of type one and two sphincter of Oddi Repeated injection of contrast material or other fluids into the main pancreatic duct Balloon dilation of an intact biliary sphincter Pancreatic sphincterotomy.
Exclusion criteria
Exclusion criteria: Pregnancy or breastfeeding Known hypersensitivity to somatostatin Liver or kidney failure Referral with manifestations of an episode of acute pancreatitis or chronic pancreatitis Use of antibiotics, antacids, and other medications that may interfere with the effects of somatostatin History of previous angina, myocardial infarction, or cerebral ischemia within the past three months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of post-ERCP pancreatitis. Timepoint: After 5 hours, and after 10 hours following ERCP. Method of measurement: Obtaining a medical history in terms of abdominal pain along with measuring serum levels of amylase and lipase. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRoham Gholami
Mashhad University of Medical Sciences
Outcome results
None listed